Dr. Justin Chihyan Pao, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 301 Andrews Ave, Fort Rucker, AL 36362 Phone: 800-261-7193 |
Dr. Sandra Lynn Griffin Banner, O.D Optometrist Medicare: Medicare Enrolled Practice Location: 33 Endl Ave, Fort Rucker, AL 36362 Phone: 229-400-1567 |
Dr. Jimmy Christopher Mcneal, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 301 Andrews Ave, Lyster Army Health Clinic - Eent, Fort Rucker, AL 36362 Phone: 334-255-7185 Fax: 334-255-7183 |
Dr. Jacqueline Nicole Balderas, OD Optometrist Medicare: Not Enrolled in Medicare Practice Location: 301 Andrews Ave, Fort Rucker, AL 36362 Phone: 334-503-7871 |
Dr. David Lee Still, O.D., PH.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 6001 Farrel Road, Usaarl, Fort Rucker, AL 36362 Phone: 334-255-0369 Fax: 334-255-6977 |
Adrienne Beth Ari, OD Optometrist Medicare: Medicare Enrolled Practice Location: Andrews Avenue, Bldg 301, Fort Rucker, AL 36362 Phone: 334-255-7185 |
James C. Dover, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 301 Andrews Avenue, Lyster Army Health Clinic, Fort Rucker, AL 36362 Phone: 334-255-7040 |
News Archive
Researchers have discovered that deletion of a specific gene permits the proliferation of new hair cells in the cochlea of the inner ear - a finding that offers promise for treatment of age-related hearing loss. This type of hearing loss is caused by aging, disease, certain drugs, and the cacophony of modern life. It is the most common cause of hearing loss in older people.
Osprey Medical Inc. (ASX: OSP) today announced that it has received U.S. FDA 510(k) clearance for its AVERTâ„¢ System.
XRC Medical Imaging (XRCMI) has announced a new rapid results program offering feedback directly to patients regarding their imaging tests within 24 hours of their appointments. XRCMI Medical Director Vu Nguyen, M.D., noted that in many cases, patients will actually get their test results before they leave from their appointment. Tests in the rapid results program include diagnostic mammograms, general X-rays and bone density tests, as well as CT and ultrasound scans.
Omeros Corporation today provided an update on OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor in development for the treatment of schizophrenia and Huntington's disease.
› Verified 6 days ago